MSN Laboratories on Friday introduced the launch of Posaconazole, a triazole antifungal agent indicated for treating Black Fungus (Mucormycosis) sufferers, in India.
MSN Laboratories on Friday introduced the launch of Posaconazole, a triazole antifungal agent indicated for treating Black Fungus (Mucormycosis) sufferers, in India.
According to a press launch issued by the corporate, MSN has launched the product below the model identify PosaOne as 100 mg Delayed Release tablets and 300 mg injections, respectively.
“As an outcome of MSN’s competence in research and manufacturing of anti-fungal infection drugs, it is now targeting to pro-actively reach patients across India by ensuring the access of PosaOne, through its strong distribution network & field force,” the city-based drug maker mentioned.
MSN has developed the lively pharmaceutical ingredient and the formulation of PosaOne in its in-house Research and Development and manufacturing models.
The drug is permitted by the Drug Controller General of India (DGCI) and matches the International high quality requirements. As a part of the COVID therapy vary, MSN has already launched Favilow (Favipiravir) within the strengths of 200mg, 400mg & 800mg, OSELOW (Oseltamivir) as 75 mg capsules and in addition licensed Baridoz (Baricitinib) just lately with Eli Lilly.
Also Read:Â Jammu & Kashmir reviews first case of black fungus
